Background The aim of this project was to collect real-world evidence and describe treatment patterns for stage III non-small cell lung cancer in Central and Eastern Europe. Based on real-world evidence, an expert opinion was developed, and the unmet needs and quality indicators were identified. Patients and methods A systematic literature search and a multidisciplinary expert panel of 10 physicians from 7 countries used a modified Delphi process to identify quality indicators and unmet needs in patients with stage III non-small cell lung cancer. The profound questionnaire was used to characterize treatment patterns used for stage III non-small cell lung cancer, and a systematic review identified patterns in Central and Eastern Europe. The first questionnaire was completed by a group of medical oncologists, radiation oncologists and pneumologists. The panel of experts attended an in-person meeting to review the results of the questionnaire and to process a second round Delphi. An additional survey was then compiled and completed by the panel. Results A complete consensus was reached by the panel of experts on a set of evidence-based clinical recommendations. The experience-based questionnaire generated a highly variable map of treatment patterns within the region. A list of unmet needs and barriers to quality care were developed with near-unanimous consent of the panel of experts. Conclusions The current landscape of diagnostic and therapeutic approaches in Central and Eastern European countries is highly variable. We identified several significant barriers, mainly related to the availability of diagnostic and imaging methods and low rates of chemoradiotherapy with curative intention as initial treatment for unresectable stage III NSCLC.

1st Faculty of Medicine of Charles University Prague Czech Republic

Department for Respiratory Diseases Jordanovac University Hospital Centre Zagreb School of Medicine University of Zagreb Zagreb Croatia

Department of Oncology and Radiotherapy Medical University of Gdansk Gdansk Poland

Department of Oncology University of Warmia and Mazury in Olsztyn Olsztyn Poland

Faculty of Medicine University of Ljubljana Ljubljana Slovenia

Institute for Oncology and Radiology of Serbia Belgrade Serbia

Institute of Oncology Ljubljana Ljubljana Slovenia

Institute of Oncology Prof Dr Ion Chiricuta Cluj Napoca Romania

National Koranyi Institute of TB and Pulmonology Budapest Hungary

Zobrazit více v PubMed

International Agency for Research on Cancer. World Health Organization. https://www.who.int/cancer/PRGlobocanFinal.pdf Press release N. 263. [cited 2020 Feb 13]. Available at.

Publications Office of the EU. Central and Eastern Europe. [cited 2020 Feb 14] https://op.europa.eu/en/web/eu-vocabularies/th-concept/-/resource/eurovoc/914 Available at.

International Agency for Research on Cancer. World Health Organization. Lung cancer. https://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf [cited 2020 Feb 15]. Available at.

Huber RM, Ruysscher DD, Hoffmann H, Reu S, Tufman A. Interdisciplinary multimodality management of stage III nonsmall cell lung cancer. Eur Respir Rev. 2019;28:190024. doi: 10.1183/16000617.0024-2019. PubMed DOI PMC

Detterbeck FC, Boffa DJ, Kim AW, Tanoue LT. The eighth edition lung cancer stage classification. Chest. 2017;151:193–203. doi: 10.1016/j.chest.2016.10.010. PubMed DOI

Goldstraw P, Chansky K, Crowley J, Rami-Porta R, Asamura H, Eberhardt WEE. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016;11:39–51. doi: 10.1016/j.jtho.2015.09.009. et al. PubMed DOI

Postmus PE, Kerr KM, Oudkerk M, Senan S, Waller DA, Vansteenkiste J. Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2017;28:iv1. doi: 10.1093/annonc/mdx222. et al. –. PubMed DOI

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer. N Engl J Med. 2017;377:1919–29. doi: 10.1056/NEJMoa1709937. et al. PubMed DOI

Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC. N Engl J Med. 2018;379:2342–50. doi: 10.1056/NEJMoa1809697. et al. PubMed DOI

Gray JE, Villegas A, Daniel D, Vicente D, Murakami S, Hui R. Three-year overall survival with durvalumab after chemoradiotherapy in Stage III NSCLC - update from PACIFIC. J Thorac Oncol. 2020;15:288–93. doi: 10.1016/j.jtho.2019.10.002. et al. PubMed DOI PMC

McMillan SS, King M, Tully MP. How to use the nominal group and Delphi techniques. Int J Clin Pharm. 2016;38:655–62. doi: 10.1007/s11096-016-0257-x. PubMed DOI PMC

Isla D, de Castro J, García-Campelo R, Lianes P, Felip E, Garrido P. Treatment options beyond immunotherapy in patients with wild-type lung adenocarcinoma: a Delphi consensus. Clin Transl Oncol. 2019;22:759–71. doi: 10.1007/s12094-019-02191-y. et al. PubMed DOI

Isla D, González-Rojas N, Nieves D, Brosa M, Finnern HW. Treatment patterns, use of resources, and costs of advanced non-small-cell lung cancer patients in Spain: results from a Delphi panel. Clin Transl Oncol. 2011;13:460–71. doi: 10.1007/s12094-011-0683-0. PubMed DOI

Darling G, Malthaner R, Dickie J, McKnight L, Nhan C, Hunter A. Quality indicators for non-small cell lung cancer operations with use of a modified Delphi consensus process. Ann Thorac Surg. 2014;98:183–90. doi: 10.1016/j.athoracsur.2014.03.001. et al. PubMed DOI

Moldaver D, Hurry M, Evans WK, Cheema PK, Sangha R, Burkes R. Development, validation and results from the impact of treatment evolution in non-small cell lung cancer (iTEN) model. Lung Cancer. 2020;139:185–94. doi: 10.1016/j.lungcan.2019.10.019. et al. PubMed DOI

Wang X, Su S, Li S, Bao H, Zhang M, Liu D. Development of quality indicators for non-small cell lung cancer care: a first step toward assessing and improving quality of cancer care in China. BMC Cancer. 2017;17:306. doi: 10.1186/s12885-017-3602-0. et al. PubMed DOI PMC

Provencio M, Carcereny E, Artal Á. Consensus on the use of immune-related response criteria to evaluate the efficacy of immunotherapy in non-small cell lung cancer. Clin Transl Oncol. 2019;21:1464–71. doi: 10.1007/s12094-019-02072-4. PubMed DOI

Milada Zemanová, Pirker R, Petruzelka L, Zbozínkova Z, Jovanovic D, Rajer M. Care of patients with non-small-cell lung cancer Stage III – the Central European real-world experience. Radiol Oncol. 2020;54:209–20. doi: 10.2478/raon-2020-0026. et al. PubMed DOI PMC

Rusu P, Ciuleanu TE, Cernea D, Pelau D, Gaal V, Cebotaru C. Concurrent chemoradiotherapy with vinorelbine and a platinum compound followed by consolidation chemotherapy for unresectable stage III non-small cell lung cancer: preliminary results of a phase II study. J BUON. 2007;12:33–9. et al. PubMed

National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology - Non-Small Cell Lung Cancer. 2020. https://www.nccn.org/professionals/physician_gls/pdf/nscl.pdf Version 5.202, 27 May. Avaiable at.

Durvalumab for treating locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation | Guidance | NICE [Internet] https://www.nice.org.uk/guidance/ta578/chapter/1-Recommendations [cited 2020 Feb 27]. Available at.

Vrankar M, Stanic K. Long-term survival of locally advanced stage III non-small cell lung cancer patients treated with chemoradiotherapy and perspectives for the treatment with immunotherapy. Radiol Oncol. 2018;52:281–8. doi: 10.2478/raon-2018-0009. PubMed DOI PMC

Ramlau R, Krawczyk P, Dziadziuszko R, Chmielewska I, Milanowski J, Olszewski W. Predictors of EGFR mutation and factors associated with clinical tumor stage at diagnosis: Experience of the INSIGHT study in Poland. Oncol Lett. 2017;14:5611–8. doi: 10.3892/ol.2017.6907. et al. PubMed DOI PMC

Podmaniczky E, Fábián K, Pápay J, Puskás R, Gyulai M, Furák J. Decreased ERCC1 Expression After Platinum-Based Neoadjuvant Chemotherapy in non-Small Cell Lung Cancer. Pathol Oncol Res. 2015;21:423–31. doi: 10.1007/s12253-014-9839-x. et al. PubMed DOI

Jeremić B.. Standard treatment option in stage III non-small-cell lung cancer: case against trimodal therapy and consolidation drug therapy. Clin Lung Cancer. 2015;16:80–5. doi: 10.1016/j.cllc.2014.08.003. PubMed DOI

Georgieva N, Bochev P, Dancheva Z, Chaushev B, Balev B, Klisarova A. PET/CT in NSCLC with brain metastases. Rentgenol Radiol. 2014;53:204–10. et al.

Zielinski M, Szlubowski A, Kołodziej M, Orzechowski S, Laczynska E, Pankowski J. Comparison of endobronchial ultrasound and/or endoesophageal ultrasound with transcervical extended mediastinal lymphadenectomy for staging and restaging of non-small-cell lung cancer. J Thorac Oncol. 2013;8:630–6. doi: 10.1097/JTO.0b013e318287c0ce. et al. PubMed DOI

Kolodziejczyk M, Kepka L, Dziuk M, Zawadzka A, Szalus N, Gizewska A. Impact of [18F]fluorodeoxyglucose PET-CT staging on treatment planning in radiotherapy incorporating elective nodal irradiation for non-small-cell lung cancer: a prospective study. Int J Radiat Oncol Biol Phys. 2011;80:1008–14. doi: 10.1016/j.ijrobp.2010.04.018. et al. PubMed DOI

Jeremić B, Miličić B, Milisavljevic S. Toxicity of concurrent hyperfractionated radiation therapy and chemotherapy in locally advanced (stage III) non-small cell lung cancer (NSCLC): single institution experience in 600 patients. Clin Transl Oncol. 2012;14:613–8. doi: 10.1007/s12094-012-0848-5. PubMed DOI

Kepka L, Bujko K, Orlowski TM, Jagiello R, Salata A, Matecka-Nowak M. Cardiopulmonary morbidity and quality of life in non-small cell lung cancer patients treated with or without postoperative radiotherapy. Radiother Oncol. 2011;98:238–43. doi: 10.1016/j.radonc.2010.09.020. et al. PubMed DOI